Currently, no FDA-approved vaccines or treatments are available for Ebola virus disease (EVD), and therapy remains largely supportive. Ebola virus (EBOV) has broad tissue tropism and can infect a variety of cells including epithelial cells. Epithelial cells differ from most other cell types by their polarized phenotype and barrier function. In polarized cells, the apical and basolateral membrane domains are demarcated by tight junctions, and specialized sorting machinery, which results in a difference in composition between the two membrane domains. These specialized sorting functions can have important consequences for viral infections. Differential localization of a viral receptor can restrict virus entry to a particular membrane while polarized sorting can lead to a vectorial virus release. The present study investigated the impact of cell polarity on EBOV infection.
Characteristics of EBOV infection in polarized cells were evaluated in the polarized Caco-2 model grown on semipermeable transwells. Transepithelial resistance (TEER), which is a function of tight junctions, was used to assess epithelial cell polarization. EBOV infection was assessed with immunofluorescence microscopy and qPCR. Statistical significance was calculated using one-way ANOVA and significance was set at p < 0.05.
Our data indicate that EBOV preferentially infects cells from the basolateral route, and this preference may be influenced by the resistance across the Caco-2 monolayer. Infection occurs without changes in cellular permeability. Further, our data show that basolateral infection bias may be dependent on polarized distribution of heparan sulfate, a known viral attachment factor. Treatment with iota-carrageenan, or heparin lyase, which interrupts viral interaction with cellular heparan sulfate, significantly reduced cell susceptibility to basolateral infection, likely by inhibiting virus attachment.
Our results show cell polarity has an impact on EBOV infection. EBOV preferentially infects polarized cells through the basolateral route. Access to heparan sulfate is an important factor during basolateral infection and blocking interaction of cellular heparan sulfate with virus leads to significant inhibition of basolateral infection in the polarized Caco-2 cell model.
Outbreaks Chronology: Ebola virus Disease. 2016. https://www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html. Accessed 26 Aug 2018.
Ebola situation reports: Democratic Republic of the Congo. http://www.who.int/ebola/situation-reports/drc-2018/en. Accessed 26 Aug 2018.
Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego, Calif). 2001;25(4):402–8. CrossRef
Anderson JM. Molecular structure of tight junctions and their role in epithelial transport. Physiology. 2001;16(3):126. CrossRef
Lindahl U. Heparan sulfate-protein interactions--a concept for drug design? Thromb Haemost. 2007;98(1):109–15. PubMed
Cagno V, Donalisio M, Bugatti A, Civra A, Cavalli R, Ranucci E, Ferruti P, Rusnati M, Lembo D. The Agmatine-containing poly(Amidoamine) polymer AGMA1 binds cell surface Heparan sulfates and prevents attachment of mucosal human papillomaviruses. Antimicrob Agents Chemother. 2015;59(9):5250–9. CrossRefPubMedPubMedCentral
- Heparan sulfate is an important mediator of Ebola virus infection in polarized epithelial cells
Dawn M. Gerhardt
Richard S. Bennett
Peter B. Jahrling
Jean L. Patterson
- BioMed Central
Neu im Fachgebiet Innere Medizin
Meistgelesene Bücher aus der Inneren Medizin
Mail Icon II